We asked three influential clinicians how they rank Arterosil in their vascular interventions.
In this short video, three practitioners - Dr. Kristine Burke, Dr. Robert Sheeler, and Dr. Mark Houston - discuss the place of Arterosil within the larger context of vascular therapeutics.
Is Arterosil foundational, essential, or nice-to-have for your patients?
Dr. Burke explained that Arterosil has become more essential in her practice as she recognized its “upstream” role in supporting vascular health, potentially replacing several “downstream” interventions.
Dr. Sheeler considers Arterosil foundational for the approximately 50% of patients at risk of cardiovascular disease.
Dr. Houston considers Arterosil as foundational for every patient. He explains that atherosclerotic disease is probably universal and begins in utero; therefore, "[Arterosil] is not only foundational, but start it soon."
Key Takeaways
- Arterosil is an “upstream” vascular intervention with multiple “downstream” benefits
- Approximately half the population is at risk of vascular impairment, and for them Arterosil is essential
- Elevated plaque burden is likely to be universal, so Arterosil holds value for every individual
In Dr. Houston’s words:
“Simple question: Who in this country — or any country — probably doesn’t have atherosclerotic cardiovascular disease?”
Learn more at our practitioner education center:
About the Participants
Dr. Kristine Burke is a family practitioner and director of the True Health Center for Functional Medicine.
Dr. Robert Sheeler is a family practitioner, director of Next Level Care, and Associate Professor at Mayo Clinic.
Dr. Mark Houston is a cardiologist and director of the Hypertension Institute and Vascular Biology.
IMPORTANT NOTICE:
The information on this webpage is for licensed healthcare practitioner education only, and is not to be disseminated to the general public.
